Andrea van Elsas, PhD
Andrea van Elsas is Chief Scientific Officer (CSO) of Aduro Biotech, Inc., following a tenure as Chief Scientific Officer of Aduro Biotech Europe (Oct 2015-Sep 2017).
Prior to its acquisition by Aduro in 2015, he co-founded BioNovion and served as Chief Scientific Officer focusing on the development of innovative therapeutic antibodies in the field of immune oncology. From 1999 to 2011, he held numerous positions at Organon in Oss, The Netherlands, and Cambridge, Massachusetts (acquired by Schering-Plough Corporation in 2007 and later by Merck & Co.). As the Director of Tumor Immunology he ran the immune oncology portfolio and led the anti-PD1 program that later became known as pembrolizumab. After concluding his thesis research in Leiden on immune recognition of ras oncogene mutations and melanoma antigens, he obtained a KWF grant to work with Jim Allison at the University of California, Berkeley, from 1997 to 1999, studying the application and mode-of-action of anti-CTLA-4 for the treatment of cancer. He is a co-inventor on the original patents that formed the basis for the development of ipilimumab, the first checkpoint inhibitor approved in 2011 by the U.S. Food and Drug Administration for the treatment of melanoma.